US Edition
Published • loading... • Updated
Eli Lilly (LLY) Stock: Company Loads Up $1.5B of Weight-Loss Pills to Battle Wegovy
Summary by Blockonomi
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eli Lilly (LLY) Stock: Company Loads Up $1.5B of Weight-Loss Pills to Battle Wegovy
TLDR Eli Lilly stockpiled $1.5 billion of Orforglipron weight-loss pill before expected April 2026 FDA approval Strategy aims to prevent supply shortages that hurt Zepbound and Mounjaro launches in 2022 Novo Nordisk’s oral Wegovy reached 50,000 prescriptions by January after December 2025 approval Orforglipron could hit $13 billion in annual sales by 2031 according to GlobalData forecasts Company investing $27 billion in four new U.S. manufactu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
